Peripheral Arteriography
4 original drugs 4
Novel Drugs
10
Reformulations
0
Active Trials
0
Drug Targets
Peripheral Arteriography has 4 FDA-approved novel treatments, led by LIEBEL-FLARSHEIM. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.
Peripheral Arteriography Market Leaders
Companies with the most FDA-approved novel Peripheral Arteriography drugs.
Novel Peripheral Arteriography Drugs by Company (New molecular entities)
2 companies have an FDA-approved novel drug for Peripheral Arteriography.
Reformulations (10 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
ULTRAVIST (PHARMACY BULK)
Bayer
T3 2002
VISIPAQUE 270
GE HEALTHCARE
T1 1996
VISIPAQUE 320
GE HEALTHCARE
T1 1996
OMNIPAQUE 140
GE HEALTHCARE
T1 1985
OMNIPAQUE 300
GE HEALTHCARE
T1 1985
OMNIPAQUE 180
GE HEALTHCARE
T1 1985
OMNIPAQUE 9
GE HEALTHCARE
T1 1985
OMNIPAQUE 350
GE HEALTHCARE
T1 1985
OMNIPAQUE 240
GE HEALTHCARE
T1 1985
OMNIPAQUE 12
GE HEALTHCARE
T1 1985
Generic Drugs (2 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs